Industry Voices—Right to Try law provides a license to cash in on patient fears
September 24, 2018 / Peter Pitts
More than 1.7 million Americans will be diagnosed with cancer this year. Almost one in three of those patients will eventually succumb to it. Knowing these odds, patients are eager to try anything to improve on them. They and their loved ones want quicker access to the latest medicines—even if they are still at an experimental stage. That's why so many Americans applauded the passage of the "Right To Try Act," which was signed by President Trump in May. The measure creates a legal pathway for terminally ill patients to access new medications that have only been through one phase of Food and Drug Administration approval.